Cybin to Host Q2 2025 Financial Results Conference Call Amid Advanced Clinical Development

Cybin Inc. will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The company describes itself as a late-stage breakthrough neuropsychiatry company focused on revolutionizing mental healthcare through developing new and innovative next-generation treatment options. This announcement comes as Cybin continues developing its pipeline of investigational compounds targeting mental health conditions.

The company is currently advancing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development timeline. Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in a Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting various mental health conditions where current treatment options remain limited.

Investors and interested parties can access the full press release at https://ibn.fm/BqH38 for complete details about the upcoming conference call. Cybin operates across multiple countries including Canada, the United States, the United Kingdom, and Ireland. The company emphasizes its commitment to addressing the large unmet need for people suffering from mental health conditions by developing novel drugs that provide effective and durable results for patients. The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN.

The upcoming financial results presentation and business update will provide stakeholders with important insights into Cybin's progress in developing potential breakthrough treatments for major depressive disorder and generalized anxiety disorder, conditions that affect millions of people worldwide and represent significant market opportunities for innovative pharmaceutical approaches. These developments are particularly important given the substantial unmet medical needs in mental healthcare and the potential for these investigational treatments to offer new options for patients who have not responded adequately to existing therapies.